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PAR5
HEALTH CARE RESOURCES UTILIZATION IN
CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
Lachaine J1, Bradley-Kennedy C2
1University of Montreal, Montreal, QC, Canada; 2Boehringer
Ingelheim Canada Ltd, Burlington, QC, Canada
Chronic Obstructive Pulmonary Disease (COPD) is
among the leading cause of death in North America.
Despite its high prevalence, morbidity and mortality, little
is known about its impact on health care resources 
utilization.
OBJECTIVES: To deﬁne the patient proﬁle for COPD
and quantify health care resource utilization of patients
with a diagnosis of COPD in term of hospitalization,
visits to the emergency department, use of medical 
services, and medications use.
METHODS: The study was conducted using data from
the Quebec Provincial Drug Plan (QPDP) databases.
From a random sample representing 10% of the popula-
tion covered by the QPDP, two different cohorts were
extracted from the databases—one comprising subjects
diagnosed with COPD and a comparison group, matched
for sex and age group, of subjects without COPD.
RESULTS: The proportion of COPD in the population
covered by the QPDP drug plan was 4.8%, with a higher
proportion among men than among women. On average
the cost difference between COPD and non-COPD was
$8,897 ($14,728 vs. $5,831) over a three-year period or
$2,966 per patient per year. In both groups costs of health
care resource increase with age, but cost in the COPD
group were higher than in the non-COPD group for each
age category. COPD patients had more days of hos-
pitalization, more visits to the emergency, more hospital
outpatient clinics and more physician visits in private
ofﬁces. In addition, the consumption of medical services
and pharmaceutical services was higher in the COPD
group than in the non-COPD group.
CONCLUSION: COPD is a frequent disease affecting a
large proportion of the elderly population and represent
a signiﬁcant burden to the health care system. Patients
with COPD use a higher quantity of health care resources
than those who are not diagnosed with COPD. This
translates into higher health care costs.
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ESTABLISHING THE RELIABILITY OF 
EVIDENCE FOR THE SIGNIFICANT IMPACT OF
ALLERGIC RHINITIS ON HEALTH RELATED
COSTS
Sullivan S1,Armstrong DS2, Ershoff D3
1Institute for Health and Productivity Management, Scottsdale,
AZ, USA; 2Integrated Therapeutics Group, La Verne, CA, USA;
3Integrated Therapeutics Group,Tarzana, CA, USA
OBJECTIVES: To describe the similarities of the magni-
tude of lost work performance related to allergic rhinitis
in multiple industries.
METHODS: 14,000 employees from 10 western U.S.
employers in four industries (local government, public
schools, gaming/casino, and healthcare/medical) were
asked to participate in a cross-sectional study of allergic
rhinitis. An anonymous, self-administered questionnaire
was distributed at the worksite and returned to a third
party to assure conﬁdentiality. The questionnaire
included items assessing allergy severity, symptoma-
tology, medication use, health service utilization, self-
management knowledge and practices, sociodemograph-
ics and lost work performance (due to full and partial
missed days and presenteeism). Response rates by 
industry ranged from 30% to 85% with 2,493 employ-
ees reporting that they currently had allergies.
RESULTS: The average age of responders ranged from 39
to 46. 92% of responders from the healthcare/medical
industry were female compared with 82% from public
schools, 66% from gaming/casinos and 63% from local
government. Approximately 75% of employees from
local government, public schools and gaming/casinos
reported moderate to severe allergies versus 60% in 
the healthcare/medical industry. On average, 25–33% of
employees across industries reported use of non-sedating
antihistamines. Despite demographic differences, there
were consistencies regarding lost work performance
across all industries ranging from 16.4 hours lost in
public schools to 18.1 in gaming/casinos. Presenteeism
accounted for the majority (75%) of these hours across
industries.
CONCLUSIONS: The replication of lost work per-
formance ﬁndings provides strong evidence of the sub-
stantial disease burden of allergic rhinitis of a diversity 
of workers across different occupational categories and
industries. This study supports estimates that lost work
performance from allergic rhinitis is four to ﬁve times
greater than direct medical expenditures and must be
included when measuring total health related costs to
employers. Allergic rhinitis, like migraines, presents a sig-
niﬁcant opportunity for employers to reduce health-
related costs via targeted interventions.
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ECONOMIC CONSEQUENCES OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN A
NATIONAL SAMPLE OF US ADULTS
Sendersky V1, Law AW2, Gause D3, Sung J3
1Duke University/Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA; 2Duke University, Durham, NC, USA;
3Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA
OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a signiﬁcant public health problem resulting 
in substantial societal burden. The main objective of this
study was to estimate direct medical costs attributable to
COPD.
METHODS: Data from the Household Component of
1996 Medical Expenditures Panel Survey (MEPS), a
nationally representative sample of the non-
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institutionalized, U.S. civilian population were analyzed.
MEPS data provided information on demographics,
health conditions, prescription medications, and health
resource utilization. Persons >= 45 years with COPD
(ICD-9 = 491 [chronic bronchitis], ICD-9 = 492 [emphy-
sema]) as their primary diagnosis were included. Direct
medical costs were deﬁned as the sum of insurance and
patient payments for health services attributable to
COPD. This included emergency department visits, 
hospital outpatient visits, inpatient stays, outpatient 
clinic and ofﬁce visits, and prescription medications.
Descriptive statistics were conducted. Results were
weighted to reﬂect population estimates.
RESULTS: In 1996, 1.4 million people over 45 years of
age received medical treatment for COPD. 65.7% of this
cohort were 65 and older. Direct medical costs attribut-
able to COPD totaled $3.4 billion. COPD-associated
direct medical costs for persons 65 and older were $3.1
billion. 77% of the total medical costs in this group of
patients were due to hospital admissions, 14.3% were for
prescription medications, and 5.5% were for emergency
room and hospital outpatient visits.
CONCLUSIONS: Inpatient admissions in the elderly
accounted for the majority of the COPD-associated costs.
Interventions designed to manage COPD more effectively,
including appropriate utilization of prescription medica-
tions, may help minimize ER visits and hospital admis-
sions, thereby decreasing total costs of managing COPD.
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COSTS AND BENEFITS ASSOCIATED WITH
INITIATION OF FLUTICASONE VERSUS
MONTELUKAST AS CONTROLLER THERAPY IN
A MEDICAID ASTHMATIC POPULATION
Balkrishnan R1, Camacho F1, Schechter MS1, Pleasants RA2,
Bowton DL1
1Wake Forest University School of Medicine, Winston-Salem,
NC, USA; 2Campbell University School of Pharmacy, Buies
Creek, NC, USA
OBJECTIVES: Outcomes in asthmatic patients may vary
depending on the controller medication used. Observa-
tional studies of outcomes of asthma therapy are needed
to understand the implications of choice of controller 
in different populations. This study compared asthma-
related health care costs and medication compliance
between patients newly started on montelukast compared
to low-dose ﬂuticasone propionate as controller therapy
in Medicaid-enrolled asthmatic patients previously using
only short-acting beta-agonists.
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients starting either ﬂuticasone propionate
44mg (FP 44), an inhaled corticosteroid, (n = 353) or
montelukast 5 and 10mg, an oral leukotriene modiﬁer, (n
= 525) in the year 1998. Patients were followed for 1-
year pre and post controller initiation for health care
service utilization, medication reﬁll patterns, and costs. A
mixed modeling procedure with indicator variables to
adjust for potential confounders was used to determine
the adjusted cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1199 ($1180 for FP, $1212 for montelukast) in
Year 1. These costs increased to $1342 ($1235 for FP,
$1415 for montelukast) in Year 2. There were no signif-
icant differences in the adjusted asthma-related health
care costs. In both groups, physician visits were signiﬁ-
cantly higher in Year 2 (50% increase for FP, 23% for
montelukast, both p < 0.01). However, even after allow-
ing for a wider compliance range for FP (50–150%) com-
pared to montelukast (80–120%), we found montelukast
users to be more compliant with therapy in Year 2 (RR:
1.97; 95% CI: 1.25, 3.13).
CONCLUSIONS: Although there were no cost or 
health care utilization differences between the two groups
in the post-controller initiation year, montelukast use was
associated with signiﬁcantly better treatment compliance
than FP use, which could have signiﬁcant implications 
for long-term patient outcomes and costs in 
Medicaid-enrolled asthmatic patients.
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COSTS AND BENEFITS ASSOCIATED WITH
ADDITION OF SALMETEROL VERSUS
MONTELUKAST TO INHALED
CORTICOSTEROID THERAPY IN A MEDICAID
ASTHMATIC POPULATION
Balkrishnan R1, Camacho F1, Schechter MS1, Pleasants RA2,
Bowton DL1
1Wake Forest University School of Medicine, Winston-Salem,
NC, USA; 2Campbell University School of Pharmacy, Buies
Creek, NC, USA
OBJECTIVES: Asthma controller therapy with multiple
controller medications is increasingly common. Data is
needed regarding the implications of the choice for a
second controller medication. The goal of this study 
was to compare asthma-related health care costs and
medication compliance between patients newly started on
montelukast compared to salmeterol as additional 
controller therapy among patients already using inhaled
corticosteroids (ICS).
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients using ICS as controller therapy (≥4
reﬁlls in year before starting additional controller) initi-
ating either salmeterol a long-acting beta agonist, (n = 97)
or montelukast, an oral leukotriene modiﬁer, (n = 101) in
the year 1998. Each group was observed for 1-year pre
and post additional controller medication initiation for
health care service utilization, medication reﬁll patterns,
and costs. A mixed modeling procedure using indicator
variables was used to determine confounder controlled
cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1955 ($2225 for salmeterol, $1695 for mon-
telukast) in year 1. These average costs did not signiﬁ-
cantly increase for either group ($2055 entire population,
